# Safety and Immunogenicity of Recombinant RSV Vaccine (CHO Cell) in Healthy Subjects Aged 18 Years and Above

> **NCT06642558** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **MAXVAX Biotechnology Limited Liability Company** · enrollment: 522 (estimated)

## Conditions studied

- Respiratory Syncytial Virus (RSV)

## Interventions

- **BIOLOGICAL:** Recombinant Respiratory Syncytial Virus Vaccine (CHO Cells)(low dose)
- **BIOLOGICAL:** Recombinant Respiratory Syncytial Virus Vaccine (CHO Cells)(high dose)
- **BIOLOGICAL:** Placebo (Saline solution)

## Key facts

- **NCT ID:** NCT06642558
- **Lead sponsor:** MAXVAX Biotechnology Limited Liability Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-11-13
- **Primary completion:** 2025-06-30
- **Final completion:** 2027-02-28
- **Target enrollment:** 522 (ESTIMATED)
- **Last updated:** 2025-06-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06642558

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06642558, "Safety and Immunogenicity of Recombinant RSV Vaccine (CHO Cell) in Healthy Subjects Aged 18 Years and Above". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06642558. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*